Latest Breaking News On - Nephrol hypertens - Page 1 : comparemela.com

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

United kingdomJ clin hypertensClin pharmacokinetNephrol hypertensDial transplantPractice guidelineDiabetes managementChronic kidney diseaseChronic kidney disClin hypertensHypertens repOpin nephrol hypertensInt repDiabetes endocrinolEnglj med

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesCatalys pacificNephrol hypertensTanabe pharmaTom weibleDavid rodmanExchange commissionGlobenewswire incDrug administrationMineralys therapeutics incElixir health public relationsAmerican heart associationJournal of the american medical associationHeart associationScientific sessionsChief medical officer

Fluid retention and heart failure in the PRECISION trial

Fluid retention and heart failure in the PRECISION trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Markusp schlaichEli lillyNephrol hypertensTravere pharmaceuticalsElsevier ltdBoehringer ingelheimOpin nephrol hypertensTravere therapeuticsChinook therapeutics

Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial

In adult kidney transplant recipients, correction of metabolic acidosis by treatment with sodium bicarbonate over 2 years did not affect the decline in estimated GFR. Thus, treatment with sodium bicarbonate should not be generally recommended to preserve estimated GFR (a surrogate marker for graft function) in kidney transplant recipients with chronic kidney disease who have metabolic acidosis.

United kingdomCity ofSemin nephrolNephrol hypertensClin nephrolNational institute for healthWork groupKidney blood press resSummary of the british transplantation society guidelinesDial transplantBlood press resInt repPreserve transplant studyIntern medOpin nephrol hypertensCare excellence

Novartis investigational oral therapy iptacopan (LNP023) receives FDA Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G

Posted December 16th, 2020 for Novartis Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disorder, resulting in debilitating symptoms that can impact patients’ quality of life 1–3 C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need 4-5 With potential to be the first oral treatment for a range of complement-driven diseases, complement factor B inhibitor iptacopan targets the underlying cause of these conditions through its action on the complement system’s alternative pathway 6,7 Iptacopan is in development for PNH, as well as C3G and several other rare renal diseases including IgA nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and membranous nephropathy (MN); first FDA filings anticipated in 2023

United statesEric althoffIsabella zinckSamir shahThomas hungerbuehlerPhil mcnamaraSloan simpsonNephrol hypertensDrug administrationNovartis oncology communicationsInternational paroxysmal nocturnal hemoglobinuria registryNovartis us external communicationsExchange commissionEuropean society for bloodMeeting of the american society nephrologyMetabolic communications